DNA X Announces $8.1M Private Placement Of 1.35M Series B Preferred Shares At $6.00/Share, Including $5M Cash And $3.1M Debt Cancellation

On June 29, 2026, DNA X, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with DNA Holdings Venture, Inc. ("DNA Holdings"), a holder of more than 5% of the Company’s outstanding capital stock and an entity associated with Scott Walker, a member of the Company’s board of directors, pursuant to which the Company agreed to issue and sell, in a private placement, 1,346,531 shares of non-voting Series B Convertible Preferred Stock, par value $0.001 per share (the "Series B Preferred Stock"), at a purchase price of $6.00 per share, for an aggregate offering price of $8.1 million consisting of $5.0 million in cash and the cancellation of $3.1 million of the outstanding balance under a convertible promissory note issued to DNA Holdings in May 2026 (the "Transaction"). Concurrently with the entry into the Purchase Agreement, the Company and DNA Holdi...